Glaxosmithkline (Finland)

Recent papers from Glaxosmithkline (Finland)

1. Total-body PET of two approved PARP inhibitors: [18F]Olaparib and [11C]Niraparib in Non-Human PrimatesEJNMMI Radiopharmacy and Chemistry · 2026
2. Consistent adherence to biologic therapies is critical for improving outcomes in asthmaJournal of Allergy and Clinical Immunology Global · 2026
3. Bepirovirsen induces innate immune proteins independent of HBVHepatology International · 2026
4. Regional risk assessment Part I: prioritization of potentially contaminated sitesIntegrated Environmental Assessment and Management · 2026
5. Unlocking herpes zoster vaccination value in Finland: return on investment and actuarial modelThe European Journal of Health Economics · 2026
6. Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signalingJHEP Reports · 2026
7. On the constancy of the fine structure constant alphaPhysics Essays · 2026
8. Prostatic tissue distribution of gepotidacin in patients undergoing prostatectomy: an ex-vivo microdialysis and pharmacokinetic modelling studyClinical Microbiology and Infection · 2026
9. Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapyInternational Journal of Gynecological Cancer · 2026
10. Impact of Preclinical Verification in Physiologically Based Pharmacokinetic Modelling for First-in-Human Predictions: Application of a Published Model Building Strategy for Five CompoundsClinical Pharmacokinetics · 2026
11. B39-16 Prevalence of Refractory Chronic Cough and Unexplained Chronic Cough in Older Adults (≥65YEARS) Based on a Claims Algorithm Using Medicare Fee-For-Service Administrative Claims DataAmerican Journal of Respiratory and Critical Care Medicine · 2026
12. A34-19 Mepolizumab Is Associated With Reductions in Exacerbations and Oral Corticosteroid Use in a Real-World Setting Among US Patients With Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine · 2026
13. A32-12 Developing Low-carbon Salbutamol MDI: Assessment of Safety and Tolerability of Salbutamol With Propellant HFA-152aAmerican Journal of Respiratory and Critical Care Medicine · 2026
14. B32-15 Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma: An Integrated Analysis of the SWIFT-1/-2 and AGILE StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026
15. B22-20 Depemokimab Demonstrates Sustained Long-term Efficacy and Consistent Patient-reported Outcomes Over 2 Years in Patients With Type 2 Asthma and Chronic Rhinosinusitis With Nasal Polyps: An Integrated Analysis of the Phase III SWIFT-1/-2 and the Open-label Extension AGILE StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026
16. A34-20 Mepolizumab Is Associated With Reductions in Healthcare Resource Utilization in a Real-world Setting Among US Patients With Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine · 2026
17. C14-09 Who Receives Biologics? Comparative Real-world Insights Into Biologic Access and Adherence in Severe Asthma in the USAAmerican Journal of Respiratory and Critical Care Medicine · 2026
18. C70-13 Depemokimab vs Mepolizumab: Immuno-PET Imaging to Evaluate the Impact of YTE Modification on Tissue Distribution in Cynomolgus MonkeysAmerican Journal of Respiratory and Critical Care Medicine · 2026
19. B39-17 Chart Review of Real-world Characteristics and Treatment Patterns of Patients With Refractory or Unexplained Chronic Cough in the United StatesAmerican Journal of Respiratory and Critical Care Medicine · 2026
20. B32-30 When Patients Stay, Outcomes Improve: Real-world Evidence From Multiple Asthma Biologic StudiesAmerican Journal of Respiratory and Critical Care Medicine · 2026